Results 41 to 50 of about 22,676 (187)

Development of a Supercritical Fluid Chromatography-Tandem Mass Spectrometry Method for the Determination of Azacitidine in Rat Plasma and Its Application to a Bioavailability Study

Molecules, 2013
Azacitidine is widely used for the treatment of myelodysplastic syndromes (MDS) and acute myelogenous leukaemia (AML). The analysis of azacitidine in biological samples is subject to interference by endogenous compounds.
Dongpo Li, Tianhong Zhang, Longfa Kou, Youxi Zhang, Jin Sun, Zhonggui He   +5 more
doaj   +1 more source

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Haematologica, 2018
Therapy of acute myeloid leukemia in older persons is associated with poor outcomes because of intolerance to intensive therapy, resistant disease and co-morbidities.
Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, CL Beach, Ravi Vij, Xiwei Wang, Jim Zhong, Robert Peter Gale   +12 more
doaj   +1 more source

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial

eJHaem, 2023
Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine in patients with
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux   +10 more
doaj   +1 more source

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply [PDF]

, 2016
There is an increasing interest on the effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes (MDS) outside clinical trials. We recently reported the lack of effect of this drug in an unselected population of 821 patients.
Bernal del Castillo, Teresa, Martínez Camblor, Pablo, Sanz, Guillermo, Sánchez García, Joaquín   +3 more
core   +1 more source

Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management

Frontiers in Oncology
Azacitidine, a hypomethylating agent, has caused a paradigm shift in the outcomes of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not eligible for stem cell transplantation, particularly in combination with BCL2 ...
Ruah Alyamany, Ahmed Alnughmush, Malak Almutlaq, Mohammed Alyamany, Mansour Alfayez   +4 more
doaj   +1 more source

Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation

Haematologica, 2016
Advanced myelodysplastic syndrome harbors a high risk of progression to acute myeloid leukemia and poor prognosis. In children, there is no established treatment to prevent or delay progression to leukemia prior to hematopoietic stem cell transplantation.
Nicolas Waespe, Machiel Van Den Akker, Robert J. Klaassen, Lani Lieberman, Meredith S. Irwin, Salah S. Ali, Mohamed Abdelhaleem, Bozana Zlateska, Mira Liebman, Michaela Cada, Tal Schechter, Yigal Dror   +11 more
doaj   +1 more source

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Platelets, 2021
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Francesco D’Alò, Ilaria Zangrilli, Elisa Cupelli, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Emiliano Fabiani, Livio Pagano, Stefan Hohaus, Valerio De Stefano   +9 more
doaj   +1 more source

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells [PDF]

, 2015
Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need. Recent data on the
Chang, Emily, Ganguly, Sudipto, Gocke, Christopher D., Konig, Heiko, Levis, Mark, Rajkhowa, Trivikram   +5 more
core   +1 more source

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

Real‐world study of the use of azacitidine in myelodysplasia in Australia

eJHaem
Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation.
Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Silar, Harold Keer, Francesco Castaldi, Taleisha Paine   +7 more
doaj   +1 more source